Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 2, 2015, Pages 208-215

  Tuohy, Orla ^a   Costelloe, Lisa ^b   Hill Cawthorne, Grant ^c   Bjornson, Ingunn ^a   Harding, Katharine ^d   Robertson, Neil ^d   May, Karen ^a   Button, Tom ^a   Azzopardi, Laura ^a   Kousin Ezewu, Onajite ^a   Fahey, Michael T ^e   Jones, Joanne ^a   Compston, D Alastair S ^a   Coles, Alasdair ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BETA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; MITOXANTRONE; RADIOACTIVE IODINE; RITUXIMAB; STEROID; THYROID PEROXIDASE ANTIBODY; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNITY; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DEATH; DISABILITY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GRAVES DISEASE; HEMOLYTIC ANEMIA; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HERPES ZOSTER OTICUS; HUMAN; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PREGNANCY; PREGNANCY OUTCOME; RECURRENCE RISK; SIDE EFFECT; SPONTANEOUS ABORTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROID GLAND; THYROIDITIS; TREATMENT DURATION; TREATMENT OUTCOME; UNITED KINGDOM; UNIVARIATE ANALYSIS; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNITY; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921319094     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-307721     Document Type: Article

References (22)

1. Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35:3332-42.
2. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83:298-304.
3. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
4. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
5. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39.
6. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691-5.
7. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-78.
8. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
9. Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol 2010;185:763-8.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
11. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119 (Pt 1):225-37.
12. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-48.
13. Matthews JN, Altman DG, Campbell MJ, et al. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
14. Liu C, Li Wan Po A, Blumhardt LD. "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:726-9.
15. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry 1999;67:451-6.
16. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000;68:450-7.
17. Neurostatus. Neurostatus. Secondary Neurostatus 2001. http://www.neurostatus.net
18. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
19. Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci USA 2013;110:20200-5.
20. Ebers GC, Heigenhauser L, Daumer M, et al. Disability as an outcome in MS clinical trials. Neurology 2008;71:624-31.
21. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009;119:2052-61.
22. Azzopardi L, Thompson SA, Harding KE, et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:795-8.